Diseases for which CBD has therapeutic benefits - World Health Organization

Alzheimer's disease
Antinflammatory, antioxidant, antiapoptotic in in vitro and in vivo models of Aβ-evoked neuroinflammatory and neurodegenerative responses.

Parkinson's disease
Attenuation of the dopaminergic impairment in vivo; neuroprotection; improvement of psychiatric rating and reduction of agitation, nightmare and aggressive behaviour in patients.

Multiple Sclerosis
Improved signs of EAE in mice, antinflammatory and immunomodulatory properties.

Huntington's disease
Neuroprotective and antioxidant in mice transgenic models

Hypoxia-ischemia injury
Short term neuroprotective effects; inhibition of excitotoxicity, oxidative stress and inflammation in vitro and in rodent models.

Analgesic in patients with neuropathic pain resistant to other treatments.

Attenuation of the behavioural and glial changes in animal models of schizophrenia; anti-psychotic properties on ketamine-induced symptoms

Reduction of muscular tension, restlessness, fatigue, problems in concentration, improvement of social interactions in rodent models of anxiety and stress; reduced social anxiety in patients.

Anti-depressant effect in genetic rodent model of depression.

Anti-proliferative and anti-invasive actions in a large range of cancer types; induction of autophagy-mediated cancer cell death; chemopreventive effects.

Suppression of nausea and conditioned gaping in rats

Antinflammatory properties in several in vitro and in vivo models; inhibition of inflammatory cytokines and pathways.

Rheumatoid Arthritis
Inhibition of TNF-α in an animal model

Activity against methicillin-resistant Staphylococcus aureus

Inflammatory bowel and Crohn's diseases
Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex vivo; reduction in disease activity index in Crohn's patients.

Cardiovascular diseases
Reduced infarct size through anti-oxidant and anti-inflammatory properties in vitro and in vivo.

Diabetic complications
Attenuation of fibrosis and myocardial dysfunction

Source: p. 18, Pizanti, et al, (2017), CANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2, Committee on Drug Dependence, Thirty-ninth Meeting, Geneva, 6-10 November 2017, World Health Organization, http://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf